Searched for
SANDOZ PHARMA
Sun Pharma shares rally 9% in two days after $12-bn Organon deal. Here's what Morgan Stanley, other brokerages saySun Pharmaceutical Industries' shares surged nearly 9% after announcing the $11.75 billion acquisition of Organon & Co., a global leader in...- ET Exclusive | Sun Pharma set to acquire Organon for $12.5 bn, its biggest till dateUS company’s board meeting is happening this weekend to finalise decision; an announcement is imminent later tonight or by Monday. Mumbai H...
- Bain Capital sole contender for Vitabiotics buyBain Capital has emerged as the frontrunner to acquire Vitabiotics, as rival bidders TPG Capital and EQT exit the process, potentially lowe...
- Strides Pharma to acquire Sandoz branded generics portfolio to expand Africa businessStrides Pharma Science is preparing to enhance its presence in Sub-Saharan Africa by acquiring branded generic products from Sandoz AG, wit...
- DART has a buy call on Sun Pharma, target price Rs 530Resolution of the US drug price fixing probe will remove a major overhang on the stock.
- Buy Aurobindo Pharma, target price Rs 485: ICICI SecuritiesTaking Sandoz out of estimates, the brokerage now expects consolidated revenue growth in mid-single digit for Aurobindo over the next two y...
- Brokerages lower Aurobindo Pharma target price by 17-27%Brokerages see the termination of the deal as a setback to scale up sales in the US .
- Buy Aurobindo Pharma, target price Rs 450: Motilal OswalThe brokerage has reduced its earnings estimate for FY21/FY22 by 19 per cent/18 per cent to Rs 51/Rs 53 to factor in termination of Sandoz ...
- Aurobindo, Sandoz call off USD 900 mn dealThe transaction if completed would have positioned the Hyderabad-based firm as the second largest dermatology player and the second largest...
- Novartis scraps sale of assets including COVID-19 hopeful to India's AurobindoNovartis AG on Thursday scrapped the $1 billion sale of U.S. generic pill and skin drug assets to India's Aurobindo Pharma Ltd as regulator...
- Aurobindo Pharma aims to become debt free in 3 years sans Sandoz dealIn September last year, the USD three billion drug maker said its US subsidiary entered into an agreement to acquire commercial operations ...
- Aurobindo’s buyout of Sandoz assets delayed on FTC queryOn Wednesday, shares of Aurobindo closed 4.8 per cent lower at Rs 450.75 on the BSE.
- Aurobindo Pharma lines up $200 million capex for FY20Aurobindo Pharma Ltd. to invest $ 200 million on Capex and over 5% of sale value on R&D.
- Buy Aurobindo Pharma, target Rs 836: Elara CapitalBuy Aurobindo Pharma Ltd. at a price target of Rs 836.
- Aurobindo buys US units of Sandoz for $900 millionThe acquired business has been carved out by the management of Sandoz for divestment.
- Aurobindo Pharma acquires dermatology business from Sandoz in a $900 million cash dealThe acquisition will add approximately 300 products including projects in development as well as commercial and manufacturing capabilities ...
- Biocon teams up with Swiss drugmaker Sandoz for next gen biosimilarUnder the terms of the agreement, both companies will share responsibility for end to end development, manufacturing and global regulatory ...
- Sun Pharma gets boost with US FDA approval for GleevecSun Pharmaceutical announced it received approval from the US FDA for generic copies of Gleevec, a drug that treats chronic myeloid leukemi...
- Natco Pharma cracks 19% as US justices agrees to hear Teva's Copaxone appealThe decision by the Supreme Court comes at a time when Teva is switching its daily version of Copaxone to twice a week version.
- Claris enters pact with Mayne, SandozContinuing with its overseas expansion plans, Ahmedabad-based pharmaceutical firm Claris Lifesciences today said it had entered into strate...
Load More
